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Abstract
Background: Recently flavonoids have attracted the attention of researchers in the fight against cancer. Calycopterin
and xanthomicrol, are two polymethoxylated flavonoids found in the aerial parts of Dracocephalum kotschyi Bioss.. We
have recently shown that these compounds possess antiangiogenic activity and may be of value as potential anticancer
agents. In order to demonstrate putative in vivo antitumor effect of these compounds we needed preliminary
information on both pharmacokinetics and toxicological properties of these two agents.
Method: A new online SPE HPLC method for measurement of calycopterin and xanthomicrol in rat plasma was
developed. Pharmacokinetic parameters of calycopterin and xanthomicrol, after i.v. administration in rats, were
determined.
Results: The plasma half-life for both agents was around 4 h, however, the volume of distribution of calycopterin
appeared to be about 8 times greater than xanthomicrol. This was probably due the greater hydrophobicity of the former
which had other consequences such as much smaller maximum plasma concentration of calycopterin compared to its
less methoxylated congener. Preliminary toxicological study of xanthomicrol failed to show any behavioral, histological
and biochemical adverse effects after repeated administrations of high doses.
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Background
The demonstration of antiproliferative effects of a number
of flavonoids against cancer cell lines, has attracted the
interest of researchers in these chemicals as potential
therapeutic agents for the prevention and/or treatment of
different forms of neoplasms [1]. The in vitro effects of
flavonoids range from being generally cytotoxic [2] to
showing selective effects against some cell lines and not
others [3]. The molecular mechanisms involved in
the cellular effects of flavonoids reflect a similar
diversity: from a change in inner mitochondrial
membrane permeability leading to cell death by
many flavonoids [4] to selective regulation of the
miR-101/MKP-1/MAPK pathway to decrease the in-
flammatory response [5] by genkwanin. Structure
activity relationship (SAR) studies have been able
to delineate the link between molecular structure
and selectibity of cytotoxic effects for some of
these compounds [6]. For example, data obtained
by Moghadam et al. [6] suggests that polymethoxy-
lated hydroxyflavones like xanthomicrol and caly-
copterin (Fig. 1) appear to have more selective
activities against cancer cell lines compared to
hydroxyflavones with no methoxy groups such as
luteolin or apigenin. It can be reasoned that a
xenobiotic with across the board cytoxicity does
not get us any nearer to finding new therapeutic
agents with less side-effects than the currently used
drugs and thus the more selective agents should be
better candidates for further research. However, as
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our knowledge about the in vitro mode of action of
these agents increases, we obtain a better understand-
ing why those flavonoids which are not globally cyto-
toxic against a multitude of malignant cell lines, may
help decrease tumor size in vivo and therefore have
potential anticancer activity with little or no direct
cytotoxic effects on neoplastic cells making up the
bulk of the tumor. Recent work in our laboratory on
calycopterin and xanthomicrol has shown these com-
pounds to possess, in addition to their selective cyto-
toxic effects, potent antiangiogenic activities which
appear to be due to inhibition of endothelial cell pro-
liferation via decreased VEGF activity [7]. The import-
ance of angiogenesis in tumor growth and metastasis
was first suggested by Folkman [8] and later demon-
strated by many other workers [9–11] and may pro-
vide an explanation for the antineoplastic effect of
many flavanoids e.g., genistein [12]. It is also worth
remembering that currently there are a number of
agents under clinical trial as antitumor drugs with
this mechanism of action [13].
The demonstration of in vitro antiangiogenic activ-
ities for these two polymethoxylated flavones has to
be followed by investigations into the in vivo an-
titumor effects of xanthomicrol and calycopterin.
However, these efforts are hampered by a lack of
pharmacokinetic and toxicological data about these
agents. In other words, we not only have to obtain
data which links administered dose to plasma flavon-
oid concentrations but also have to provide prelim-
inary evidence on the lack of overt toxicity. This
study was undertaken to achieve these goals.
Methods
Plant material
Aerial parts of Dracocephalum kotschyi Bioss. were ob-
tained from a herbalist in the city of Isfahan and the
identity of the specimen was confirmed by Dr Gh Amin,
Faculty of Pharmacy, Tehran University of Medical
Sciences (voucher specimen number at the faculty of
pharmacy herbarium: PMP-304).
Isolation and purification of xanthomicrol and
calycopterin, identity confirmation, recovery calculations
Xanthomicrol and calycopterin were isolated and
purified as previously reported [6] with some modifi-
cations to the HPLC step. Briefly, 10 kg of dried aer-
ial parts of Dracocephalum kotschyi Bioss. were
manually powdered and extracted in 50 g batches by
overnight extraction with 400 mL ethyl acetate using
a Soxhelt apparatus. The extract aliquots from 10 kg
plant material were dried in vacuo, combined and fi-
nally dissolved in 8 L chloroform and filtered through
Whatman No. 1 filter paper to remove particulate
matter. The flavonoid content was extracted in 1 L
batches into 1 L 1 M ammonia solution. The in-
tensely yellow ammonia solution was acidified to
pH 1 using concentrated HCl and the flavonoid con-
tent was back extracted into 200 mL ethylacetate.
The non-methoxylated hydroxyflavones were removed
by treatment with alumina. The organic solvent was
evaporated in vacuo. The material obtained in this
step was subjected to semipreparative HPLC purifica-
tion as follows. A 10 μm Nucleosil ODS column from
Macherey Nagel (21x250mm) was equilibrated with a
mobile phase containing 37 % ACN, 24 % MeOH,
38.5 % Water and 0.5 % triethylamine, adjusted to
pH 6 with acetic acid. A saturated solution of the ex-
tract in mobile phase was centrifuged at 10000 g for
5 min and 1.7 mL of the supernatant was injected
onto the column. The column eluent (5 mL/min) was
monitored at 226 nm using a LKB Uvicord UV de-
tector connected to a Younglin (Younglin, South
Korea) data acquisition module. Fractions containing
xanthomicrol, calycopterin and circimaritin were col-
lected and dried by lyophilization. Peak identities
were confirmed by infrared spectroscopic analysis [6].
The flavones content (μg per gram of dried aerial
parts of the plant material) was calculated. Purity of
isolated compounds was examined using analytical
HPLC on a 4.6x150mm, ODS-2, 5 μm, Tracer Excell
column (Technochroma, Spain) using the same mo-
bile phase as described above, pumped isocratically
while detecting at 263 nm.
Fig. 1 Structures of calycopterin and xanthomicrol
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Analytical HPLC method for measurement of xanthomicol
and calycopterin
Confirmation of calycopterin, xanthomicrol and circi-
maritin identity was carried out using HPLC analysis of
purified compound compared to the material obtained
from previous work [6] and also IR spectroscopy. A
HPLC method with online solid phase extraction was
developed for the analysis of xanthomicrol and calycop-
terin in biological fluids (Fig. 1) using circimaritin as in-
ternal standard (IS). 100 μL of plasma and 10 μL of
500 μg/mL IS were mixed in a 2 mL microcentrifuge
tube. 40 μL of 10 mg/mL ZnSO4 was added to the tube
and the content was mixed. After addition of 200 μL
acetonitrile, the tube was placed in an orbital shaker for
10 min. The samples were subsequently centrifuged at
14000 g for 10 min the supernatant was subjected to on-
line extraction/HPLC analysis as follows:
At the start of every run, the sample injection valve and
the sample extraction valve were switched to load position
(Fig. 1). 250 μL of sample was injected into the sample
loop of the sample injection valve. The valve was switched
to the inject position which diverted the flow from the on-
line SPE (solid phase extraction) solvent delivery pump
(500 μL/min) through the sample loop which in turned
carried the sample onto the online SPE column (3×15mm,
ODS-2, 5 μm). After 2 min, the sample extraction valve
was switched to inject position. This allowed the mobile
phase from the analysis solvent delivery pump (1 mL/min)
to wash any material retained by the online SPE system,
onto the analytical column (4.6×150mm, ODS-2, 5 μm,
Tracer Excell, Technochroma, Spain) for separation and
measurement. The mobile phase pumped by online SPE
solvent delivery pump consisted of acetonitrile:water
(35:65) and the mobile phase pumped by the analysis
solvent delivery pump was composed of acetonitrile:-
methanol:water:triethylamine (37:24:38.5:0.5). 16 min after
the start of analysis, the mobile phase pumped by the ana-
lysis solvent delivery pump was switched to methanol:te-
trahydrofurane:dichloromethane (80:10:10) for 3 min.
This allowed for highly non-polar compounds retained by
the SPE and analytical column to be flushed. Detection
was at 263 nm.
The assay system was calibrated for both xanthomicrol
and calycopterin over the concentration range of 125 to
1500 ng/mL. In order to estimate the recovery of the
assay, the calibration curve with online SPE was com-
pared to a standard curve injected directly into the ana-
lytical column, without the SPE step. Inter-day and
intra-day variation and S/N ratio were calculated for this
analytical system.
Rat femoral vein cannulation
All procedures involving animals were carried out after
the approval and under the supervision of the Ethics
Committee for Animal Expreiments of Iran University
for Medical Sciences. In order to be able to withdraw
blood samples at predefined time points during pharma-
cokinetic studies, femoral vein of male Wistar rats, in
the weight range of 280 to 300 g, were catheterized,
Fig. 2 Schematic diagram of the fluidics of the online solid phase extraction HPLC system
Table 1 Flavone content of Dracocephalum kotschyi Bioss. dried
aerial parts
Flavone Specific amount
(μg flavone / g plant material)
Xanthomicrol 95.2
Calycopterin 38
Circimaritin 15
Zamani et al. DARU Journal of Pharmaceutical Sciences  (2016) 24:22 Page 3 of 10
under anaesthesia, using the method described by
Jespersen et al. [14]. After the placement of the catheter,
the animals were allowed to recover for 24 h, during
which time, the rats were checked for signs of bleeding
and the catheters were checked for patency.
Pharmacokinetic study
Xanthomicrol or calycopterin was dissolved in 200 μL
of dimethylsulfoxide (DMSO) and injected into the
dorsal tail vein of rats. Just before drug injection
(time zero) and at 1, 5, 10, 20, 60, 120 and 240 min
after drug injection, 300 μL of blood were withdrawn
via the femoral vein which had been catheterized pre-
viously. In order to prevent phlebotomy induced
hypovolemia, 200 μL normal saline was injected via
the femoral catheter after each blood sample with-
drawal. Blood samples were centrifuged at 4 °C for
10 min at 4000 g. Plasma was collected and stored
frozen at -80 °C until needed.
Toxicological studies in mice
Toxicity studies were carried out using Balb/C mice
in the 25-30 g weight range. Drug administration
was via the I.P. methoud. Animals were assigned to
five groups of three: one-Control groups which re-
ceived no treatment, two-Vehicle control which re-
ceived 60 μL of DMSO (dimethyl sulfoxide) for
6 days, 3- Test group one which received 30 mg/kg
body weight xanthomicrol in 60 μL of DMSO per
day, 4- Test group two which received 40 mg/kg
body weight xanthomicrol on 60 μL of DMSO per
day and 5- Test group three which received 50 mg/
kg body weight xanthomicrol on 60 μL of DMSO
per day. The animals were weighed and examined
for changes in skin tone, signs of fur loss and
changes in bowl function [15]. On the seventh day,
the animals were anaesthetized under an atmosphere
of chloroform. Once fully anaesthetized, blood sam-
ples were collected from the heart and the animals
were killed by cervical dislocation. Serum samples
were analyzed for hepatic enzymes AST and ALT
[16] and also for creatinin levels [17]. Kidneys, liver,
lung, intestines and stomach were removed from an-
imals and placed in 10 % formalin solution for sub-
sequent paraffin embedding, sectioning, staining and
histological studies. Tissue sections were examined
for fibrotic, inflammatory and vascular changes by a
qualified pathologist [18].
Fig. 3 Purity of isolated flavonoids as determined by analytical HPLC. The inset shows a preparative chromatogram of Dracocephalum kotschyi
Biossy flavonoid fraction
Table 2 Validation parameters for the HPLC assay of calycopterin and xanthomicrol
Compound Calibration Equation
Y =mX + C, R2
Interday at
500 ng/mL
Intraday at
500 ng/mL
LOD (ng/mL)
(S/N) = 3
LOQ (ng/mL)
(S/N) = 10
Calycopterin Y = 0.0002X + 0.0014 4.3 % 2.5 % 10 34
R2 = 0.998
Xanthomircol Y = 0.0001X + 0.0023 3.9 % 2.2 % 8 32
R2 = 0.999
S/N, signal to noise ratio
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Results
Isolation and purification of xanthomicrol, calycopterin
and circimaritin, identity confirmation
Processing of 10 kg of dried aerial parts of Dracocephalum
kotschyi Bioss. yielded 476 mg of xanthomicrol, 190 mg of
calycopterin and 60 mg of circimaritin. The compounds
obtained appeared to be pure as demonstrated by the ex-
istence of single peak in HPLC analysis (Fig. 2). The iden-
tities of isolated flavones were confirmed HPLC analysis
and IR spectroscopy in comparison with standard material
previously obtained [6]. The flavones contents were deter-
mined (Table 1).
Analytical HPLC method for measurement of xanthomicol
and calycopterin
Plasma samples spiked with calycopterin (125 to
1500 ng/mL) or xanthomicrol (125 to 2000 ng/mL) were
extracted as described above and subsequently analyzed
by analytical HPLC using online extraction (Fig. 3). Both
calibration curves were linear over the concentration
ranges described (Table 2). Recovery of the extraction
method was investigated by comparing the peak areas of
500 ng/mL of calycopterin and xanthomicrol and
1430 ng/mL circimaritin (as IS) obtained from injection
of mixtures using the on-line SPE method with the same
flavone mixtures injected directly onto the analytical
column, without the online solid phase extraction step.
Recoveries of calycopterin and xanthomicrol were 94 %
and 92 % respectively.
Pharmacokinetic study
Figure 4 shows the plots of plasma flavones concentration
against time for both xanthomicrol and calycopterin. For
both xanthomicrol and calycopterin, two-compartment
models were found to adequately describe the changes in
concentration with time (Fig. 5). Pharmacokinetic parame-
ters obtained from constructing the residual concentration
verses time curve for these two-compartmental models are
presented in Table 3. Rate constants for transfer between
the central and peripheral compartments (K21and K12) and
also the elimination process (Kel) were also calculated.
Toxicological studies in mice
There were no significant differences in serum creatinin
content, alanine transaminase (ALT) and aspartic acid
transaminase (AST) activities between control, vehicle and
test groups of mice which had received xanthomicrol at 30,
40 or 50 mg/kg body weight (Table 4). The weight of
animals in control group (27.1 g ± 1.2), on different days,
were not significantly different compared to the animals in
xanthomicrol groups (27.7 ± 1.7 g), on corresponding days.
Histological examination of tissue samples from
kidney, small and large intestines, lung and heart of test
animals showed absence of significant pathological
change in animals receiving xanthomicrol compared to
the control group (Fig. 6) (Table 5).
Discussion
The research into the proposed antineoplastic properties
of Spinal-Z, an Iranian herbal remedy, composed of pega-
num harmala seeds extracted and Dracocephalum kotschyi
Bioss. leaves extract has been going on in our laboratory
for more than 15 years. The inhibitory effects of β-
carbolines found in peganum harmala seeds on topoisom-
erase activity [19] was demonstrated first, however, further
work suggested a more prominent role for selective
Fig. 4 Calibration curve for xanthomicrol (○) and calycopterin (●)
spiked in plasma. The values are mean ± SEM for three
independent analyses
Fig. 5 Plasma concentration-time profile of calycopterin (●) and
xanthomicrol (○) in rats after IV administration of 20 mg/kg of the
flavnoid. Values are mean ± SEM, n = 4
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cytotoxic activity of flavonoids found in Dracocephalum
kotschyi Bioss. leaves extract [20]. Recently we were able
to show calycopterin and xanthomicrol to have anti-
angiogenic activity in ex vivo and in vitro models of angio-
genesis [7]. Although there is some data suggesting
antineoplastic effects for xanthomicrol in mice (data
not published), in order to proceed to investigate the
in vivo antineoplastic effects of calycopterin and
xanthomicrol, one has to have information about
pharmacokinetic parameters of these two flavonoids,
particularly the maximum attainable plasma concen-
tration after a particular dose and drug half-life. Also
any toxic effects they may possess in whole animals
will be of great interest. The current work was car-
ried out to furnish such data.
In order to speed up the purification process and in-
crease the productivity of the semi-preparative HPLC
purification, the procedure for extraction, isolation and
purification of xanthomicrol and calycopterin reported
previously [6] was modified. Inclusion of an alumia treat-
ment step after alternate alkali/acid extraction of the flava-
noid fraction, helped remove the unmethoxylated
hydroxyflavones. This treatment, decreased the complex-
ity of the extract to the extent that a new mobile phase
containing triethylamine could be used for the semi-
preparative HPLC phase. The solubility of the crude ex-
tract in the new mobile phase was about 10 times greater
than the previously reported simple mobile phase,
which meant that during each semi-preparative HPLC
step, 10 times greater quantities of calycopterin and
xanthomicrol were obtained. Also, the change in mo-
bile phase helped shorten the run time to 70 min
compared to the previously reported 125 min. Taken
together, the efficiency of the new purification process
was increased by about 20 fold. However, the total re-
covery of xanthomicrol, calycopterin and circimaritin,
were similar to what had been reported previously
(Table 1) [6].
During the pharmacokinetic study, one has to with-
draw multiple blood samples from the test animal over a
few hours. In order to ensure relatively constant physio-
logical homeostasis during the pharmacokinetic study, it
is best to withdraw as little a blood sample as possible.
This in turn means a small amount of plasma harvested
for analytical purposes, typically about 100 μL for the
rat, increasing the sensitivity and repeatability constrains
of the assay method. Therefore, in order to measure
calycopterin and xanthomicrol in rat plasma, a HPLC
method was developed and validated that utilized online
solid phase extraction, offering enhanced sensitivity and
improved low-concentration precision. The method was
simple in that plasma deprotination was acheived by
addition of zinc sulphate and acetonitrile. The total vol-
ume of deproteinated sample was 350 μL, of which, after
centrifugation, 250 μL was injected onto the column. In
other words, the content of greater that 70 % of the
plasma sample was loaded onto the analytical HPLC col-
umn, maximizing the total material loaded. Also, the on-
line SPE, concentrated the sample’s flavonoid content,
helping tominimize band broadening through the analyt-
ical column, again enhancing the detection and quantifi-
cation limits of the assay (Table 2). Although the
quantitation of xanthomicrol or calycopterin in plasma
has not been reported before, workers have measured
other flavanoids in human or animal serum: Busby et al.
[21] used 1000 μL of human serum to measure isofla-
vones genistein and daidzein. They achieved a LOQ of
1.7 and 3 μg/mL for genistein and daidzein respectively.
These values are approximately 30 times higher than
those obtained for xanthomicrol and calycopterin in the
current work. Biasutto [22] measured quercetin in rat
plasma. Using 200 μL samples and a sample deproteina-
tion step involving solvent extraction, they achieved a
LOQ of 50 ng/mL for this flavonoid [22]. This is similar
to the value obtained in the present work, however, their
method was more elaborate and time consuming.
The assay thus developed in this study was applied to
the pharmacokinetic study of xanthomicrol and calycop-
terin in rats. The I.V. route for drug administration was
Table 3 Pharmacokinetic parameters for xanthomicrol and calycopterin after i.v. bolus administration to rats
C0 (μg/L) Vc (L) t1/2 (h) K21 (h
-1) K12 (h
-1) Kel (h
-1) Cla (L/h)
Calycopterin (20 mg/kg) 312 63.9 3.8 0.52 1.39 0.26 16.8
Xanthomicrol (20 mg/kg) 2345 8.5 4.2 0.46 1.88 0.21 1.8
C0: Initial plasma concentration; Vc: Volume of distribution of the central compartment; thalf: Biological half-life; K21: Rate constant of transfer from the central com-
partment into the peripheral compartment; K12: Rate constant of transfer from the peripheral compartment into the central compartment; Kel: Rate constant of
elimination from the central compartment, Cla: Clearance rate of the central compartment
Table 4 Effects of different doses of xanthomicrol on kidney
and liver functions
Group Serum Creatinin
(mg/mL)
Serum ALT
(IU/L)
Serum AST
(IU/L)
Control 0.36 ± 0.019 43 ± 15 180 ± 48
Vehicle 0.35 ± 0.015 49 ± 29 228 ± 94
30 mg/kg
Xanthomicrol
0.36 ± 045 38 ± 8.8 138 ± 37
40 mg/kg
Xanthomicrol
0.35 ± 0.036 22 ± 19 130 ± 49
50 mg/ kg
Xanthomicrol
0.39 ± 0.02 30 ± 3.0 316 ± 163
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chosen because this ensured all administered dose would
reach the systemic circulation, without the need to take
into account loss during oral absorption and less than
complete bioavailability. Therefore the data obtained
from I.V. administration of the flavonoids, would give
more direct estimates of pharmacokinetic parameters of
interest in this study which would enable us to design
more valid in vivo antitumor assays for these two agents.
Both agents are relatively hydrophobic and thus do
not dissolve in water based solvent systems. A number
of solvents which were able to dissolve xanthomicrol
and calycopterin were investigated as vehicles for the de-
livery of these compounds into the blood stream. DMSO
was chosen as it is relatively benign in terms of toxico-
logical effects (a number of drug formulations or
medical devices containing DMSO are marketed e.g.,
RIMSO-50 from Bioniche Pharma, USA and Dolicur
from Schering, Germany). Also, the volume required as
vehicle (200 μL) was small compared to total blood vol-
ume in rat (about 20 mL) and would be unlikely to have
an appreciable effect on pharmacokinetics of flavonoids
being studied.
In order to keep to a predefined sample withdrawal
schedule, a cannula was inserted into the rat’s vein at
least 24 h before pharmacokinetic study. Cannulation
procedure for the femoral artery [14] proved to be easier
than that of the carotid artery with faster recovery of the
animal after the procedure. Blood sampling schedule
was designed to ensure there were enough samples in
the initial period after drug administration, during which
time changes in drug concentration were likely to be
rapid. Plots of the logarithm of both calycopterin and
xanthomicrol plasma concentrations verses time were
not linear which suggested that the one compartment
model would be unsuitable for analysis of concentration
data. Two compartment analyses were successfully
applied.
Calycopterin has one methoxy group more than
xanthomicrol and is thus expected to be more hydro-
phobic. This is confirmed by the longer retention
time of the former during reverse phase chromatog-
raphy (Fig. 3). However, the extent of the effect of
this increased hydrophobicity on disposition of caly-
copterin in rat, was unexpected. When administered
at 20 mg/kg, xanthomicrol had a calculated initial
plasma concentration of 2345 μg/L while the corre-
sponding value for calycopterin was 312 μg/L
(Table 3). This is probably because, compared to
xanthomicrol, calycopterin distributes more rapidly
into various organs thus leaving blood or the “central
compartment” in our model, more quickly. This,
which is also reflected in the difference in the Vc
Fig. 6 Schematic representation of the two-compartment pharmacokinetic model used to analyse the concentration data. Cp: Plasma concentration;
V: Volume of distribution of the central compartment; D” Drug dose, K21: Rate constant of transfer from the central compartment into the peripheral
compartment; K12: Rate constant of transfer from the peripheral compartment into the central compartment; Kel: Rate constant of elimination from the
central compartment. A, B, α,β are hybrid constants. A and B are estimated from the intercepts on log plasma concentration axis of the best fit line of
the distribution phase and elimination phase respectively. α and β are estimated from the slopes on log plasma concentration axis of the best fit line
of the distribution phase and elimination phase respectively
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values for these flavonoids (Table 3), is also confirmed
by the difference in the K12 rate constants. The rate
constant for transfer of calycopterin into the central
compartment is smaller than that of xanthomicrol
which suggests a tendency for calycopterin to distrib-
ute more easily into tissues. The elimination rate con-
stants are not very different, which may explain
similar t1/2 of elimination for these two flavonoids
(Table 3).
Our previous research had shown that at 500 ng/
mL, both calycopterin and xanthomicrol inhibited
capillary-like tube formation by HUVEC cell [7]. Our
aim in this work was to find doses of these flavonoids
which could produce such plasma levels over ex-
tended periods. This would let us investigate the in
vivo effects of these compounds on experimentally
induced tumors at therapeutically relevant plasma
concentrations. The models generated, were used to
predict the plasma concentration-time profiles for dif-
ferent doses of calycopterin and xanthomicrol (Fig. 7).
After a single I.V. dose of 30 mg/kg, xanthomicrol
plasma concentration would be greater than 500 ng/
Fig. 7 Predicted plasma calycopterin (●) and xanthomicrol (○)
concentration-time profiles after a single IV bolus dose of 30 mg/kg
or either compound in the rat. The values were calculated based
upon the two compartment models developed in this work
Table 5 Effects of different doses of xanthimcrol on tissue histology
Animal Tissue Inflammation structural change Fibrosin Vascular change Notes
Vehicle 1 Lung/Liver/Heart/ Kidney Absent Absent None Normal
Vehicle 2 Small intestine/ Large
intestine/ Gastric wall
Focal inflammation in gastric wall Absent None Normal
Vehicle 3 Lung/Liver/Heart/ Kidney Absent Absent Hypermic Increased type II
pneumocytes
Test
group
1,1
Small intestine/ Large
intestine/ Gastric wall
Absent Absent None Normal
Test
group 1,
2
Lung/Liver/Heart/ Kidney Absent Absent None Normal
Test
group 1,
3
Small intestine/ Large
intestine/ Gastric wall
Absent Absent None Normal
Test
group 2,
1
Lung/Liver/Heart/ Kidney Focal inflammation in lung tissue Absent Increased vascularization
in lung sample
Increased type II
pneumocytes
Test
group 2,
2
Small intestine/ Large
intestine/ Gastric wall
Absent Absent None Normal
Test
group
2,3
Lung/Liver/Heart/ Kidney Lymphocyte infilteration in lung sample,
Subcapsular inflammation in liver sample
Absent Hypermic Normal
Test
group
3,1
Small intestine/ Large
intestine/ Gastric wall
Absent Absent None Increased type II
pneumocytes
Test
group
3,2
Lung/Liver/Heart/ Kidney Focal inflammation in lung sample Absent None Increased type II
pneumocytes
Test
group
3,3
Lung/Liver/Heart/ Kidney Absent Absent None Normal
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mL for more than 6 h while calycopterin’s plasma
concentration would dip below 500 ng/mL 30 min
after administration.
The pharmacokinetic superiority, in terms of max-
imum attainable concentration and the time it took
to leave the central compartment, meant that
xanthomicrol had the greater potential as an anti-
angiogenic agent. Thus, the potential toxic effects of
xanthomicrol at 30, 40 and 50 mg/kg/day for six
days, were studied. As none of the animals displayed
xanthomicrol induced toxic effects with in the first
24 h after the highest dose, this flavonoid appears
not to have acute toxic effects. None of the animal
died in any of the administered dose groups. After
six days of drug treatment, none of the animals AST
levels, which are indicative of liver damage, were not
significantly different amongst control, vehicle and
test groups. Histological examination (Fig. 8) was
unable to find xenobiotic induced damage to vital
organs. There was no change in animal weights
compared to control group and no animal showed
any signs of motor or behavioral abnormalities.
Xanthomicrol, at administered doses, did not appear
to have toxic effects in mice. However, it is import-
ant to remember that this study did not attempt to
determine LD50 value for xanthomicrol or show long
term safety. Future toxicological studies must deter-
mine LD50 and also examine sub-acute and chronic
toxic effects.
Conclusion
Both calycopterin and xanthomicrol have anti-
angiogenic properties however, our data suggests that
from a pharmacokinetic point of view, xanthomicrol has
greater potential as an antitumor agent.
Fig. 8 Effect of xanthomicrol treatment on vital organ histology in mice. Images on the left have been selected from animals treated with
50 mg/kg xanthomicrol and images on the right are from control animals. a and b Liver, c and d Lung, e and f Stomach wall, g and h Heart
muscle, i and j Small intestine, k and l Kidney
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